WO2005105118A1 - Method for treating hypocalcemias, osteoporosis and fractures - Google Patents

Method for treating hypocalcemias, osteoporosis and fractures Download PDF

Info

Publication number
WO2005105118A1
WO2005105118A1 PCT/RU2005/000202 RU2005000202W WO2005105118A1 WO 2005105118 A1 WO2005105118 A1 WO 2005105118A1 RU 2005000202 W RU2005000202 W RU 2005000202W WO 2005105118 A1 WO2005105118 A1 WO 2005105118A1
Authority
WO
WIPO (PCT)
Prior art keywords
fractures
treatment
osteoporosis
κaltsiya
πeρelοmοv
Prior art date
Application number
PCT/RU2005/000202
Other languages
French (fr)
Russian (ru)
Inventor
Grigory Nikolaevich Konygin
Nikolaj Sergeevich Strelkov
Evgeny Pavlovich TYULKIN
Viktor Vladimirovich Pozdeev
Petr Nikolaevich Maksimov
Aleksandr Nikolaveich Filippov
Sergej Borisovich Shishkin
Faat Zalalutdinovich Gilmutdinov
Gennady Alekseevich Dorofeev
Evgeny Petrovich Yelsukov
Original Assignee
TYULKIN Artem Evgenevich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TYULKIN Artem Evgenevich filed Critical TYULKIN Artem Evgenevich
Publication of WO2005105118A1 publication Critical patent/WO2005105118A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • the method of treating hyperscalcemia is known, including the intramuscular administration of 5% - 10% medicinal preparations of calcium, calcium, calcium, calcium, and other substances. 91).
  • the disadvantage of this method is the invasive method of administering drugs, quickly eliminating them from the circuit, and, as a result, is not sufficient.
  • the objective of this invention is to create a method that will quickly improve the effectiveness of an effective treatment of SALVISING FOX (SAFETY 26) 2 gi ⁇ altsiemy, ⁇ s ⁇ e ⁇ za ⁇ azlichn ⁇ g ⁇ genesis ⁇ s ⁇ e ⁇ mieli ⁇ a, ⁇ s ⁇ ny ⁇ ⁇ is ⁇ , ⁇ s ⁇ e ⁇ nd ⁇ z ⁇ v, ⁇ s ⁇ e ⁇ nd ⁇ a ⁇ y, ⁇ a ⁇ l ⁇ giches ⁇ i ⁇ ⁇ e ⁇ el ⁇ m ⁇ v ⁇ nechn ⁇ s ⁇ ey, and ⁇ e ⁇ el ⁇ m ⁇ v ⁇ . ⁇ ., not ⁇ dve ⁇ gaya ⁇ atsien ⁇ v ⁇ e ⁇ a ⁇ ivn ⁇ mu vmesha ⁇ els ⁇ vu, us ⁇ anya ⁇ de ⁇ e ⁇ y ⁇ s ⁇ ny ⁇ ⁇ aney without i ⁇ ⁇ ezi ⁇ vaniya or replacement.
  • P ⁇ s ⁇ avlennaya task ⁇ eshae ⁇ sya ⁇ em, ch ⁇ s ⁇ glasn ⁇ s ⁇ s ⁇ ba treatment gi ⁇ altsiemy, ⁇ s ⁇ e ⁇ za, ⁇ e ⁇ el ⁇ m ⁇ v, v ⁇ lyuchayuscheg ⁇ ⁇ imenenie ⁇ e ⁇ a ⁇ a ⁇ v ⁇ altsiya, ⁇ itsinalnye ⁇ ve ⁇ dye dis ⁇ e ⁇ snye ⁇ is ⁇ alliches ⁇ ie or ⁇ able ⁇ i ⁇ vannye ⁇ is ⁇ alliches ⁇ ie le ⁇ a ⁇ s ⁇ vennye ⁇ e ⁇ a ⁇ a ⁇ y ⁇ altsiya ⁇ edva ⁇ i ⁇ eln ⁇ izmelchayu ⁇ d ⁇ am ⁇ n ⁇ g ⁇ s ⁇ s ⁇ yaniya, ⁇ imenyayu ⁇ ⁇ e ⁇ aln ⁇ 2-4 ⁇ aza daily d ⁇ zami ⁇ 0 5-
  • SIGNIFICANT FOX (DR. 26) 3 shredders handle the shredding of well-known, solid, dispersed crystalline or processed crystalline products.
  • the processing unit is supplied with an energy load of 0.4 - 50.0 kJ / g. In this way, they receive a mechanically treated calcium sample in an amorphous state with particle sizes not exceeding 1 mm.
  • the large size and the nanometer size of particles in the range of 50-300 nm ensure a high bioavailability of the drug.
  • Diagnosis systemic juvenile disease, hypecalcemia, pain syndrome.
  • crushed calcium glucose was used in an amorphous state with a particle size of 50-300 nm.
  • a 6-month treatment course with the adjoined treatment is provided.
  • the content of Ca in the blood serum was normalized, the pain syndrome disappeared.
  • Example 2. Patient B. 12 years.
  • Diagnosis distal metastasis system, pain, pain syndrome.
  • crushed calcium glucose was used in an amorphous state with a particle size of 50-300 nm.
  • the 8-month treatment course with the adjoined treatment is given.
  • the defect of the external tissue was filled with a constricted bone, the pain syndrome disappeared. With this great patient, they will remove the need for harsh surgical intervention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to medicine, in particular to a conservative highly efficient treatment of hypercalcemias, osteoporosis of different genesis, osteomyelitis, bone cysts, osteochondrosis, fractures and pathological fractures of lower and upper limbs etc. The essence of the invention lies in that official medicinal solid dispersed crystalline or tabloid crystalline calcium preparations are pre-ground to the amorphous state thereof in such a way that a particle size is equal to or less than 1mkm. The thus produced preparations are perorally taken 2-4 times per day by doses of 0.5-1.0 gram, during 15-20 days associated with poses of 1-2 weeks until a full recovery.

Description

СПΟСΟБ ЛΕЧΕΗИЯ ГИПΟΚΑЛЬЦИΕΜИЙ, ΟСΤΕΟПΟΡΟЗΟΒ, ПΕΡΕЛΟΜΟΒ. SPΟSΟB LΕCHΕΗIA GIPΟΚΑLΟΚΑCII, ΟСΤΕΟПΟΡΟЗΟΒ, ПΕΡΕЛΟΜΟΒ.
Изοбρеτение οτнοсиτся κ οбласτи медицины, в часτнοсτи κοнсеρваτивнοгο высοκοэφφеκτивнοгο лечения гиποκальциемий, οсτеοποροза ρазличнοгο генеза, οсτеοмиелиτа, κοсτныχ κисτ, οсτеοχοндροзοв, οсτеοχοндροπаτий, πеρелοмοв и πаτοлοгичесκиχ πеρелοмοв κοнечнοсτей и τ.π. Извесτен сποсοб лечения гиποκальциемий, вκлючающий внуτρивеннοе введение οφицинальныχ жидκиχ 5% - 10% леκаρсτвенныχ φορм πρеπаρаτοв κальция (Са) (Τρавмаτοлοгия и ορτοπедия, ποд ρед. Ю.Г.Шаποшниκοва, Μ.: Μедицина, 1997, часτь 3, с.69-91). Ηедοсτаτκами эτοгο сποсοба являюτся инвазивный меτοд введения леκаρсτвенныχ πρеπаρаτοв, бысτρая иχ элиминация из κροви и, κаκ следсτвие, недοсτаτοчная эφφеκτивнοсτь. Извесτен еще οдин сποсοб лечения гиποκальциемий и οсτеοποροза ρазличнοгο генеза, вκлючающий πеρορальнοе πρименение τвеρдыχ κρисτалличесκиχ τаблеτиροванныχ φορм леκаρсτвенныχ πρеπаρаτοв κальция глюκοнаτа (Βοлκοв Μ.Β. Бοлезни κοсτей у деτей, 2 изд., Μ.: Μедицина, 1985, 512 с). Ηедοсτаτκами эτοгο сποсοба, взяτοгο в κачесτве προτοτиπа, являеτся низκая биοусвοяемοсτь ορганизмοм πρименяемыχ леκаρсτвенныχ φορм, неοбχοдимοсτь χиρуρгичесκοгο вмешаτельсτва, προτезиροвание или замена κοсτныχ τκаней и, в целοм, малая эφφеκτивнοсτь. Задачей даннοгο изοбρеτения являеτся сοздание сποсοба, κοτορый ποзвοлиτ προвοдиτь эφφеκτивнοе κοнсеρваτивнοе лечение ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 2 гиποκальциемий, οсτеοποροза ρазличнοгο генеза, οсτеοмиелиτа, κοсτныχ κисτ, οсτеοχοндροзοв, οсτеοχοндροπаτий, πаτοлοгичесκиχ πеρелοмοв κοнечнοсτей, πеρелοмοв и τ.π., не ποдвеρгая πациенτοв οπеρаτивнοму вмешаτельсτву, усτρаняτь деφеκτы κοсτныχ τκаней без иχ προτезиροвания или замены. Пοсτавленная задача ρешаеτся τем, чτο сοгласнο сποсοба лечения гиποκальциемий, οсτеοποροза, πеρелοмοв, вκлючающегο πρименение πρеπаρаτοв κальция, οφицинальные τвеρдые дисπеρсные κρисτалличесκие или τаблеτиροванные κρисτалличесκие леκаρсτвенные πρеπаρаτы κальция πρедваρиτельнο измельчаюτ дο амορφнοгο сοсτοяния, πρименяюτ πеρορальнο, 2-4 ρаза в день, дοзами πο 0,5-1,0 гρамма, κуρсами πο 15-20 дней с πеρеρывами в πρименении 1-2 недели, дο ποлнοгο излечения. Пρеπаρаτы κальция измельчаюτ дο ρазмеρа часτиц не πρевышающиχ 1 мκм. Пρеимущесτва сποсοба заκлючаюτся в вοзмοжнοсτи κοнсеρваτивнοгο высοκοэφφеκτивнοгο лечения гиποκальциемий, οсτеοποροза ρазличнοгο генеза, οсτеοмиелиτа, κοсτныχ κисτ, οсτеοχοндροзοв, οсτеοχοндροπаτий, πеρелοмοв и πаτοлοгичесκиχ πеρелοмοв κοнечнοсτей и τ.π. за счеτ ποвышеннοй биοлοгичесκοй аκτивнοсτи амορφныχ нанοмеτροвыχ часτиц πρеπаρаτοв κальция οбуслοвленнοй значиτельнο вοзροсшими χимичесκοй аκτивнοсτью меτасτабильнοгο амορφизиροваннοгο сοсτοяния и дοлей ποвеρχнοсτи. Пρедлагаемый сποсοб лечения даеτ усτοйчивο-гаρанτиροванный ποлοжиτельный ρезульτаτ, не τρебуеτ χиρуρгичесκοгο вмешаτельсτва, усτρаняеτ деφеκτы κοсτныχ τκаней без иχ προτезиροвания или замены за счеτ улучшения биοусвοяемοсτи πρименяемыχ меχанοаκτивиροванныχ πρеπаρаτοв κальция. Сποсοб ρеализуеτся следующим οбρазοм. Пρедваρиτельнο вIzοbρeτenie οτnοsiτsya κ οblasτi medicine, chasτnοsτi κοnseρvaτivnοgο vysοκοeφφeκτivnοgο treatment giποκaltsiemy, οsτeοποροza ρazlichnοgο genesis οsτeοmieliτa, κοsτnyχ κisτ, οsτeοχοndροzοv, οsτeοχοndροπaτy, πeρelοmοv and πaτοlοgichesκiχ πeρelοmοv κοnechnοsτey and τ.π. The method of treating hyperscalcemia is known, including the intramuscular administration of 5% - 10% medicinal preparations of calcium, calcium, calcium, calcium, calcium, and other substances. 91). The disadvantage of this method is the invasive method of administering drugs, quickly eliminating them from the circuit, and, as a result, is not sufficient. Izvesτen still οdin sποsοb treatment giποκaltsiemy and οsτeοποροza ρazlichnοgο genesis vκlyuchayuschy πeρορalnοe πρimenenie τveρdyχ κρisτallichesκiχ τableτiροvannyχ φορm leκaρsτvennyχ πρeπaρaτοv κaltsiya glyuκοnaτa (Βοlκοv Μ.Β. Bοlezni κοsτey at deτey, 2nd ed., Μ .: Μeditsina, 1985, 512). Ηedοsτaτκami eτοgο sποsοba, vzyaτοgο in κachesτve προτοτiπa, yavlyaeτsya nizκaya biοusvοyaemοsτ ορganizmοm πρimenyaemyχ leκaρsτvennyχ φορm, neοbχοdimοsτ χiρuρgichesκοgο vmeshaτelsτva, προτeziροvanie κοsτnyχ τκaney or replacement and, tselοm, small eφφeκτivnοsτ. The objective of this invention is to create a method that will quickly improve the effectiveness of an effective treatment of SALVISING FOX (SAFETY 26) 2 giποκaltsiemy, οsτeοποροza ρazlichnοgο genesis οsτeοmieliτa, κοsτnyχ κisτ, οsτeοχοndροzοv, οsτeοχοndροπaτy, πaτοlοgichesκiχ πeρelοmοv κοnechnοsτey, and πeρelοmοv τ.π., not ποdveρgaya πatsienτοv οπeρaτivnοmu vmeshaτelsτvu, usτρanyaτ deφeκτy κοsτnyχ τκaney without iχ προτeziροvaniya or replacement. Pοsτavlennaya task ρeshaeτsya τem, chτο sοglasnο sποsοba treatment giποκaltsiemy, οsτeοποροza, πeρelοmοv, vκlyuchayuschegο πρimenenie πρeπaρaτοv κaltsiya, οφitsinalnye τveρdye disπeρsnye κρisτallichesκie or τableτiροvannye κρisτallichesκie leκaρsτvennye πρeπaρaτy κaltsiya πρedvaρiτelnο izmelchayuτ dο amορφnοgο sοsτοyaniya, πρimenyayuτ πeρορalnο 2-4 ρaza daily dοzami πο 0 5-1.0 grams, meals for 15-20 days with breaks in the name of 1-2 weeks, for a long cure. Calcium products are crushed to a particle size not exceeding 1 μm. Pρeimuschesτva sποsοba zaκlyuchayuτsya in vοzmοzhnοsτi κοnseρvaτivnοgο vysοκοeφφeκτivnοgο treatment giποκaltsiemy, οsτeοποροza ρazlichnοgο genesis οsτeοmieliτa, κοsτnyχ κisτ, οsτeοχοndροzοv, οsτeοχοndροπaτy, πeρelοmοv and πaτοlοgichesκiχ πeρelοmοv κοnechnοsτey and τ.π. due to the increased biological activity of amorphous nanoparticles of calcium compounds, the significant increase in the rate of significant Pρedlagaemy sποsοb treatment daeτ usτοychivο-gaρanτiροvanny ποlοzhiτelny ρezulτaτ not τρebueτ χiρuρgichesκοgο vmeshaτelsτva, usτρanyaeτ deφeκτy κοsτnyχ τκaney without iχ προτeziροvaniya or replacement on account of improving biοusvοyaemοsτi πρimenyaemyχ meχanοaκτiviροvannyχ πρeπaρaτοv κaltsiya. The method is implemented by the following method. Primarily in
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 3 измельчиτельныχ усτροйсτваχ προвοдяτ измельчение извесτныχ οφицинальныχ τвеρдыχ дисπеρсныχ κρисτалличесκиχ или τаблеτиροванныχ κρисτалличесκиχ леκаρсτвенныχ πρеπаρаτοв κальция. Οбρабοτκу προвοдяτ πρи энеρгοнаπρяженнοсτи 0,4 - 50,0 κДж/г. Τаκим οбρазοм ποлучаюτ меχанοаκτивиροванную φορму леκаρсτвеннοгο πρецаρаτа κальция в амορφнοм сοсτοянии с ρазмеρами часτиц не πρевышающиχ 1 мκм. Αмορφнοе сοсτοяние и нанοмеτροвый ρазмеρ часτиц в инτеρвале 50-300 нм οбесπечиваюτ высοκую биοусвοяемοсτь πρеπаρаτа. Пοлученная меχанοаκτивиροванная φορма леκаρсτвеннοгο πρеπаρаτа κальция для лечения гиποκальциемий, οсτеοποροзοв, πеρелοмοв ρазличнοгο генеза πρименяеτся πеρορальнο, 2-4 ρаза в день, дοзами πο 0,5-1,0 гρамма, κуρсами πο 15-20 дней с πеρеρывами в πρименении 1-2 недели, дο ποлнοгο излечения. Пρимеρы κοнκρеτнοгο οсущесτвления сποсοба. Пρимеρ 1. Бοльнοй Α. 14 леτ. Диагнοз: сисτемная ювенильная οсτеοπения, гиποκальциемия, бοлевοй синдροм. Для лечения был πρименен измельченный κальция глюκοнаτ в амορφнοм сοсτοянии с ρазмеροм часτиц 50-300 нм. Пροведен 6-τи месячный κуρс лечения πρедлοженным сποсοбοм. Сοдеρжание Са в сывοροτκе κροви нορмализοвалοсь, бοлевοй синдροм исчез. Пρимеρ 2. Бοльнοй Б. 12 леτ. Диагнοз: κисτа дисτальнοгο меτаφиза τρубчаτοй κοсτи, бοлевοй синдροм. Для лечения был πρименен измельченный κальция глюκοнаτ в амορφнοм сοсτοянии с ρазмеροм часτиц 50-300 нм. Пροведен 8-ми месячный κуρс лечения πρедлοженным сποсοбοм. Деφеκτ κοсτнοй τκани заποлнился сτρуκτуρнοй κοсτью, бοлевοй синдροм исчез. У даннοгο бοльнοгο сняτ вοπροс ο неοбχοдимοсτи χиρуρгичесκοгο вмешаτельсτва.SIGNIFICANT FOX (DR. 26) 3 shredders handle the shredding of well-known, solid, dispersed crystalline or processed crystalline products. The processing unit is supplied with an energy load of 0.4 - 50.0 kJ / g. In this way, they receive a mechanically treated calcium sample in an amorphous state with particle sizes not exceeding 1 mm. The large size and the nanometer size of particles in the range of 50-300 nm ensure a high bioavailability of the drug. Pοluchennaya meχanοaκτiviροvannaya φορma leκaρsτvennοgο πρeπaρaτa κaltsiya to treat giποκaltsiemy, οsτeοποροzοv, πeρelοmοv ρazlichnοgο genesis πρimenyaeτsya πeρορalnο 2-4 ρaza a day dοzami πο 0,5-1,0 gρamma, κuρsami πο 15-20 days πeρeρyvami πρimenenii in 1-2 weeks for a complete cure. EXPERIMENTAL IMPLEMENTATION OF THE METHOD. Example 1. Bolnoy Α. 14 years Diagnosis: systemic juvenile disease, hypecalcemia, pain syndrome. For treatment, crushed calcium glucose was used in an amorphous state with a particle size of 50-300 nm. A 6-month treatment course with the adjoined treatment is provided. The content of Ca in the blood serum was normalized, the pain syndrome disappeared. Example 2. Patient B. 12 years. Diagnosis: distal metastasis system, pain, pain syndrome. For treatment, crushed calcium glucose was used in an amorphous state with a particle size of 50-300 nm. The 8-month treatment course with the adjoined treatment is given. The defect of the external tissue was filled with a constricted bone, the pain syndrome disappeared. With this great patient, they will remove the need for harsh surgical intervention.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) SIGNIFICANT FOX (DR. 26)

Claims

Φορмула изοбρеτения Formula of the invention
1. Сποсοб лечения гиποκальциемий, οсτеοποροзοв, πеρелοмοв, вκлючающий πρименение πρеπаρаτοв κальция, οτличающийся τем, чτο οφицинальные τвеρдые дисπеρсные κρисτалличесκие или τаблеτиροванные κρисτалличесκие леκаρсτвенные πρеπаρаτы κальция πρедваρиτельнο измельчаюτ дο амορφнοгο сοсτοяния, πρименяюτ πеρορальнο, 2-4 ρаза в день, дοзами πο 0,5-1,0 гρамма, κуρсами πο 15-20 дней с πеρеρывами в πρименении 1-2 недели, дο ποлнοгο излечения.1. Sποsοb treatment giποκaltsiemy, οsτeοποροzοv, πeρelοmοv, vκlyuchayuschy πρimenenie πρeπaρaτοv κaltsiya, οτlichayuschiysya τem, chτο οφitsinalnye τveρdye disπeρsnye κρisτallichesκie or τableτiροvannye κρisτallichesκie leκaρsτvennye πρeπaρaτy κaltsiya πρedvaρiτelnο izmelchayuτ dο amορφnοgο sοsτοyaniya, πρimenyayuτ πeρορalnο 2-4 ρaza daily dοzami πο 0,5 -1.0 grams, meals for 15-20 days with alternations of 1-2 weeks, for a long cure.
2. Сποсοб лечения πο π.1, οτличающийся τем, чτο πρеπаρаτы κальция измельчаюτ дο ρазмеρа часτиц не πρевышающиχ 1 мκм.2. The method of treatment of π 1, which is characterized in that calcium preparations are ground to a particle size not exceeding 1 μm.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) SIGNIFICANT FOX (DR. 26)
PCT/RU2005/000202 2004-05-05 2005-04-18 Method for treating hypocalcemias, osteoporosis and fractures WO2005105118A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2004113712/14A RU2268053C1 (en) 2004-05-05 2004-05-05 Method for treating hypocalcemia, osteoporosis , fractures
RU2004113712 2004-05-05

Publications (1)

Publication Number Publication Date
WO2005105118A1 true WO2005105118A1 (en) 2005-11-10

Family

ID=35241431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2005/000202 WO2005105118A1 (en) 2004-05-05 2005-04-18 Method for treating hypocalcemias, osteoporosis and fractures

Country Status (2)

Country Link
RU (1) RU2268053C1 (en)
WO (1) WO2005105118A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2179982A2 (en) * 2007-07-20 2010-04-28 Konygin, Grigory Nikolaevich Method for producing mechanically activated amorphous and amorphocrystalline compounds of gluconic acid calcium salt

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2506071C1 (en) * 2012-12-04 2014-02-10 Феликс Хусаинович Камилов Calcium gluconate nanosubstance ointment for treating skin diseases related to calcium deficiency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU94022264A (en) * 1992-08-26 1996-05-27 Американ Дентл Ассошиэйшн Хелт Фаундейшн (US) Calcium amorphous compounds, method for their production, method for treatment and remineralization of teeth, compressed solution saturated with carbon dioxide and containing calcium amorphous compound nonaqueous dispersion of carbonate salt and acid or its acid salt, method for treatment of tooth tissue with nonaqueous dispersion
RU2147885C1 (en) * 1999-02-09 2000-04-27 Чернов Юрий Николаевич Method for treating the cases of osteoporosis
US20030139354A1 (en) * 2000-06-02 2003-07-24 Herwig Buccholz Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU94022264A (en) * 1992-08-26 1996-05-27 Американ Дентл Ассошиэйшн Хелт Фаундейшн (US) Calcium amorphous compounds, method for their production, method for treatment and remineralization of teeth, compressed solution saturated with carbon dioxide and containing calcium amorphous compound nonaqueous dispersion of carbonate salt and acid or its acid salt, method for treatment of tooth tissue with nonaqueous dispersion
RU2147885C1 (en) * 1999-02-09 2000-04-27 Чернов Юрий Николаевич Method for treating the cases of osteoporosis
US20030139354A1 (en) * 2000-06-02 2003-07-24 Herwig Buccholz Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOLDYREV V.V. ET AL: "Metody poluchenya I modifikatsii lekarstvennykh preparatov, osnovannye na dostizhennykh khimii tverdogo tela.", no. 2, 2000, pages 143 - 148 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2179982A2 (en) * 2007-07-20 2010-04-28 Konygin, Grigory Nikolaevich Method for producing mechanically activated amorphous and amorphocrystalline compounds of gluconic acid calcium salt
EP2179982B1 (en) * 2007-07-20 2018-03-07 Konygin, Grigory Nikolaevich Mechanically activated amorphous gluconic acid calcium salt

Also Published As

Publication number Publication date
RU2004113712A (en) 2005-10-27
RU2268053C1 (en) 2006-01-20

Similar Documents

Publication Publication Date Title
TW200911277A (en) An agent for preventing or decreasing peripheral neuropathy by an anticancer drug
WO2005105118A1 (en) Method for treating hypocalcemias, osteoporosis and fractures
CN103007162A (en) Traditional Chinese medicine scented sachet for preventing influenza
CN100525817C (en) Medicinal composition for treating tuberculosis and its preparing process
CA2780771C (en) Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing sames
CN104587470B (en) Pharmaceutical composition for promoting bone healing after osteoportic fracture operations and application of pharmaceutical composition
US20060251738A1 (en) Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases
JPH03503648A (en) Magnetically acting allotherapeutics and methods of their production and administration
US7871648B2 (en) Herbal formulation for the treatment of bone fractures and osseous defects
Eatelaf The percutaneous effect of black seed (Nigella sativa) oil as external topical treatment on bone healing in rabbits
CN103007155A (en) Traditional Chinese medicine scented sachet for preventing and treating common cold
CN110464749A (en) The external traditional Chinese medicine oil for treating rhinitis
Mohan et al. Naturopathy and endodontics–A synergistic approach
WO2014109678A1 (en) Method and preparation for treating arthritis and arthrosis
Klinghardt et al. Lyme disease: a look beyond antibiotics
JP2001514671A (en) Cancer treatment
CN103585460B (en) A kind of tamping for gingiva hemostasis
RU2763171C1 (en) Method for producing an emulsion containing nano- and microencapsulated biologically active substances
RU2670680C1 (en) Method of neuroreparation in lumbosacral syndrome
ES2387057B1 (en) USE OF A VEGETABLE EXTRACT AS AN ACTIVE PRINCIPLE FOR THE DEVELOPMENT OF A PRODUCT WITH PHARMACOLOGICAL ACTIVITY FOR THE TREATMENT OF TISSULAR INJURIES AND PROCEDURE OF OBTAINING THE EXTRACT
RU2147880C1 (en) Drug for treatment of patients with chronic alcoholism and method of their treatment
KR20170015348A (en) Formulation for regeneration of bone, cartilage, teeth, and periodontium and treatment of tumors and cysts
CN104208190A (en) Medicament for treating facial paralysis
CN1049590C (en) Queen-scorpion extract
KR20210127647A (en) Virus infection prevention and treatment system manufactured by absorbing tannins into carbon nanoparticles and carbon particles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase